東北大学大学院医学系研究科・医学部

STAFF

Professor

• Kawarura, SadafumiProfessor. 川村 貞文 教授
  

CONTACT

OUTLINE

The Division of Urologic Oncology, established at Miyagi Cancer Center Research Institute, is a collaborative chair with Tohoku University Graduate School of Medicine. We focus mainly on clinical research in the field of malignant urogenital tumors (prostate, kidney, bladder, testicular, renal pelvis and ureter, adrenal, and penile cancers). By taking advantage of its extensive dataset obtained from numerous cases, the Division of Urologic Oncology is dedicated to medical practice, research, and education regarding surgical therapy, for the most part, along with chemotherapy and radiation therapy, as well as other areas such as quality of life (QOL) investigations. We also emphasize preventive medicine, and have been working on mass screening for prostate cancer since early on. Through utilization of the admission system for working adults offered by Tohoku University Graduate School, it is possible to accumulate clinical learning experiences as a full-time doctor or resident at Miyagi Cancer Center, while working towards a doctorate degree by conducting basic research at its research institute. In this way, the Division of Urologic Oncology aims at fostering urologists with a balance of experiences in both basic and clinical domains.

泌尿器科腫瘍学分野は宮城県立がんセンター研究所に設置された連携講座で、尿路性器悪性腫瘍（前立腺癌、腎癌、膀胱癌、精巣腫瘍、腎盂尿管癌、副腎腫瘍、陰茎癌）の臨床が主な研究領域です。
豊富な症例を生かして、手術療法を中心に癌化学療法、放射線療法などの他、QOL調査などの診療、研究、教育に取り組んでいます。
また早期から前立腺がん検診にも取り組むなど、予防医学にも力を注いでいます。
当分野では東北大学大学院社会人入学制度を活用することで、宮城県立がんセンターにおいて常勤医あるいはレジデントとして臨床の研鑽を積みながら、同時に当センター研究所で基礎研究を行って博士号を取得することが可能です。
このようにして当分野では基礎と臨床のバランスのとれた泌尿器科医を育てることを目標にしています。

• 

  Da Vinci Xi surgical system
  ダヴィンチXiサージカルシステム

• 

  3D-MRI/TRUS Image Prostate biopsy System（BioJet）
  MRI/TRUS 3-D融合画像ガイド下経会陰式前立腺生検システム（BioJet）

• 

  BioJet image fusion function workflow
  BioJet画像融合機能のワークフロー

ARTICLE

Shiota M, et al, Japanese Urological Oncology Group (JUOG). Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients. Cancer Sci. 112(4):1524-1533, 2021
URL：https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019198/

Okamoto T, et al. Impact of pretreatment anemia on upfront abiraterone acetate therapy for metastatic hormone-sensitive prostate cancer: a multicenter retrospective study. BMC Cancer. 21(1):605, 2021
URL：https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8152305/

Numakura K, et al. Outcomes of axitinib versus sunitinib as first-line therapy to patients with metastatic renal cell carcinoma in the immune-oncology era. Cancer Med. 10(17):5839-5846, 2021
URL：https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419787/

Narita, T, et al. Therapeutic effects of the combined androgen blockade therapy versus luteinizing hormone-releasing hormone analog monotherapy in patients with hormone naive metastatic prostate cancer: a multi-institutional comparative analysis. Transl Androl Urol. 10(1): 417-425, 2021
URL：https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844496/

Naito S, et al. Prognosis of Japanese metastatic renal cell carcinoma patients in the targeted therapy era. Int J Clin Oncol. 26(10):1947-1954, 2021
URL：https://link.springer.com/article/10.1007%2Fs10147-021-01979-9